Morgan Stanley
BEAM icon

Morgan Stanley’s Beam Therapeutics BEAM Stock Holding History

Morgan Stanley’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67M Buy
1,950,969
+1,302,705
+201% +$39.3M ﹤0.01% 1945
2026
Q1 		$15.4M Sell
648,264
-81,136
-11% -$2.25M ﹤0.01% 3188
2025
Q4 		$20.2M Buy
729,400
+84,640
+13% +$2.16M ﹤0.01% 2923
2025
Q3 		$15.6M Sell
644,760
-662,396
-51% -$13.2M ﹤0.01% 3120
2025
Q2 		$22.2M Buy
1,307,156
+484,195
+59% +$8.43M ﹤0.01% 2695
2025
Q1 		$16.1M Buy
822,961
+27,642
+3% +$724K ﹤0.01% 2914
2024
Q4 		$19.7M Sell
795,319
-412,438
-34% -$10.5M ﹤0.01% 2763
2024
Q3 		$29.6M Buy
1,207,757
+403,928
+50% +$10.4M ﹤0.01% 2396
2024
Q2 		$18.8M Sell
803,829
-3,319,746
-81% -$81.5M ﹤0.01% 2736
2024
Q1 		$136M Sell
4,123,575
-60,767
-1% -$1.89M 0.01% 990
2023
Q4 		$114M Buy
4,184,342
+3,662,213
+701% +$91M 0.01% 1074
2023
Q3 		$12.6M Sell
522,129
-313,063
-37% -$8.39M ﹤0.01% 2905
2023
Q2 		$26.7M Buy
835,192
+105,064
+14% +$3.41M ﹤0.01% 2165
2023
Q1 		$22.4M Buy
730,128
+81,024
+12% +$3.2M ﹤0.01% 2303
2022
Q4 		$25.4M Buy
649,104
+127,984
+25% +$5.73M ﹤0.01% 2105
2022
Q3 		$24.8M Sell
521,120
-82,370
-14% -$4.7M ﹤0.01% 1977
2022
Q2 		$23.4M Buy
603,490
+52,024
+9% +$2.07M ﹤0.01% 2116
2022
Q1 		$31.6M Buy
551,466
+75,378
+16% +$4.94M ﹤0.01% 1661
2021
Q4 		$37.9M Buy
476,088
+17,464
+4% +$1.5M ﹤0.01% 1548
2021
Q3 		$39.9M Buy
458,624
+156,990
+52% +$15.8M 0.01% 1454
2021
Q2 		$38.8M Buy
301,634
+93,439
+45% +$7.44M 0.01% 1513
2021
Q1 		$16.7M Buy
208,195
+152,117
+271% +$14.5M ﹤0.01% 2104
2020
Q4 		$4.58M Buy
56,078
+19,487
+53% +$958K ﹤0.01% 3357
2020
Q3 		$901K Buy
36,591
+15,891
+77% +$394K ﹤0.01% 4281
2020
Q2 		$579K Buy
20,700
+19,004
+1,121% +$410K ﹤0.01% 4524
2020
Q1 		$30K Buy
+1,696
New +$36.9K ﹤0.01% 5659

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley's BEAM Position: Q2 2026 in Review

Morgan Stanley increased its Beam Therapeutics (BEAM) stake by 201% in Q2 2026, buying an estimated $39.3M and bringing the position to 1,950,969 shares worth $67M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Morgan Stanley first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $136M in Q1 2024. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Morgan Stanley held 1,950,969 shares of Beam Therapeutics worth $67M as of Q2 2026.
  • Morgan Stanley bought 1,302,705 Beam Therapeutics shares in Q2 2026, an estimated $39.3M.
  • Beam Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1945 holding.
  • Morgan Stanley first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Morgan Stanley's Beam Therapeutics position peaked at $136M in Q1 2024.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.